Modalities
Comprehensive End-to-End Solutions
Zelltherapie
Gentherapie
Therapeutische Antikörper
Antikörper Wirkstoff Konjugat
Impfstoffe
- Entdeckung und Entwicklung
- CMC - Herstellung
- CMC - Qualitätskontrolle
- Vorklinische Studie
- Klinische Studien
Cell Culture Products
CAR-Zielproteine
Universelle CAR-Nachweisreagenzien
MHC-Peptid-Komplexe
Aneuro: Proteine für die Neurowissenschaften
ComboX: Streptavidin (SA) Reihe
GMP-grade Growth Factors
Extracellular Matrix (ECM) Proteins
Serum-free Cell Culture Medium
Disposable Accessories
Cell Activation
Gene Editing
CAR-Zielproteine
Anti-Linker Antibodies
Safety Testing Platform
CMC-Rückstandsnachweiskits
Flow Cytometry Analysis Platform
Antikörperdichtebestimmung auf Trägersystemen
Our Commitment
ACROBiosystems' Core Brand Values
- QUALITY
- INNOVATION
- SERVICE
As we prepare for an international multicentric controlled Phase 3 study evaluating the safety and efficacy of ProtheraCytes in post-acute myocardial infarction patients, we chose ACROBiosystems GMP proteins for their level of documentation, quality control, and regulatory compliance to meet our future commercialization demands.
QUALITY Customer Story
Ibon Garitaonandia, Ph.D., MBA
Chief Scientific Officer, CellProthera
Our Global Reach
Dedicated Local Support, Always on Standby
- Offices
- R&D Centers
- Manufacturing Bases
- Logistics Hubs
London, United Kingdom
Frankfurt, Germany
Paris, France
Basel, Switzerland
Boston, MA, USA
Newark, DE, USA
San Diego, CA, USA
Beijing, China
Seoul, South Korea
Nanjing, China
Suzhou, China
Shanghai, China
Tokyo, Japan
Hangzhou, China
Hong Kong, China
San Jose, CA, USA
Customers
Locations
Employees
- Events
- Activities
North America
ASGCT Annual Meeting 2026
Learn MoreEurope
ISSCR Annual Meeting 2026
Learn MoreAsia Pacific
